EUVIMEDEUVIMED entdecken
Vergleichsstudie

Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective

Xueshan Sun, Xuemei Zhen, Shuyan Gu, Kaijie Liu, Wenqianzi Yang, Hengjin Dong

Expert Review of Pharmacoeconomics & Outcomes Research · 2025

DOI: 10.1080/14737167.2024.2410973 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Expert Review of Pharmacoeconomics & Outcomes Research, 2025. Verfasst von Xueshan Sun und 5 weiteren Autor:innen. Beteiligte Einrichtung: School of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, Shaanxi, China. Hauptthemen laut MEDLINE: Duloxetine Hydrochloride, Osteoarthritis. Die Arbeit nennt 60 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To estimate the cost-utility of duloxetine compared with that of a placebo, common traditional nonsteroidal anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 (COX-2) inhibitors for the treatment of osteoarthritis (OA) from a Chinese healthcare perspective. METHODS: A Markov model was constructed. The costs and utility inputs were obtained from the database and published literature. Incremental cost-effectiveness ratio (ICER) was the main model outputs. Subgroup analyses were also conducted for patients at high risk of gastrointestinal (GI) or cardiovascular (CV) AEs. Deterministic and probabilistic sensitivity analyses were performed. RESULTS: The model estimated an ICER of $3409.21/QALY for duloxetine compared with etoricoxib, with duloxetine dominating other active treatment strategies in patients at a low risk of GI and CV AEs. The ICER for duloxetine over etoricoxib was $322.21/QALY in patients at high risk of GI and CV AEs. These results were consistent with the sensitivity analyses; 53.64% and 53.93% of the patients were willing to use duloxetine comparing with etoricoxib, for which the thresholds were 1.0 and 3.0 per capita gross domestic product (GDP), respectively. CONCLUSIONS: Duloxetine is a valuable option for patients with OA; however, uncertainties exist in the model, and these suggestions can be adopted with caution.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Duloxetine HydrochlorideOsteoarthritisHumansCost-Benefit AnalysisEtoricoxibMarkov ChainsChinaCyclooxygenase 2 InhibitorsQuality-Adjusted Life YearsAnti-Inflammatory Agents, Non-SteroidalGastrointestinal DiseasesCardiovascular DiseasesPyridinesSulfones

Stichwörter der Autor:innen

DuloxetineNSAIDscost-utility analysisosteoarthritispharmacoeconomic model

Substanzen

Duloxetine HydrochlorideEtoricoxibCyclooxygenase 2 InhibitorsAnti-Inflammatory Agents, Non-SteroidalPyridinesSulfones

Autor:innen und Institutionen

  • School of Public Policy and Administration, Xi'an Jiaotong University, Xi'an, Shaanxi, China.
  • School of Health Care Management, Shandong University, Jinan, Shandong, China.
  • NHC Key Laboratory of Health Economics and Policy Research (Shandong University), Jinan, Shandong, China.
  • Center for Health Policy and Management Studies, School of Government, Nanjing University, Nanjing, Jiangsu, China.
  • Taizhou Hospital of Zhejiang, Linhai, Zhejiang, China.
  • Center for Health Policy Studies, School of Public Health, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.

Zitieren

APA

Sun, X., Zhen, X., Gu, S., Liu, K., Yang, W., & Dong, H. (2025). Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective. Expert Review of Pharmacoeconomics & Outcomes Research. https://doi.org/10.1080/14737167.2024.2410973

Vancouver

Sun X, Zhen X, Gu S, Liu K, Yang W, Dong H. Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective. Expert Review of Pharmacoeconomics & Outcomes Research. 2025. doi:10.1080/14737167.2024.2410973

BibTeX
@article{Sun2025,
  author = {Sun, Xueshan and Zhen, Xuemei and Gu, Shuyan and Liu, Kaijie and Yang, Wenqianzi and Dong, Hengjin},
  title = {Cost-utility analysis of duloxetine in osteoarthritis: from Chinese healthcare perspective},
  journal = {Expert Review of Pharmacoeconomics & Outcomes Research},
  year = {2025},
  doi = {10.1080/14737167.2024.2410973}
}
Kostenlos starten →